Drug
Dtx401
Dtx401: highest development phase Phase 3, developed by Ultragenyx Pharmaceutical. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Ultragenyx Pharmaceutical
Trials
| Drug | Phase | Indication |
|---|---|---|
| DTX401 NCT05139316 | Phase 3 | Glycogen Storage Disease Type IA |
| DTX401 NCT03517085 | Phase 1/2 | GSD1 |
Latest
No recent events.
Follow Dtx401 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.